Other safety alerts
|
| |
| Australia: Miracle Mineral Solution (MMS): Safety advisory: false and misleading claims relating to COVID-19 |
| |
The Therapeutic Goods Administration (TGA) is warning consumers to be alert to misleading claims made online about Miracle Mineral Solution (MMS) for the treatment, cure, prevention or alleviation of disease in humans, including COVID-19.
MMS is often marketed as water purification drops and may be offered under different names, including Miracle Mineral Supplement. It contains a high concentration of sodium chlorite, which is a chemical used as a textile bleaching agent and disinfectant. Products containing high concentrations of sodium chlorite pose a serious health risk if consumed by humans and should be labelled with the appropriate warnings. MMS has not been approved by the TGA for use to treat, cure, prevent or alleviate any disease or condition. In Australia, products that are used in the purification or treatment of drinking water, and are not marketed with therapeutic claims, are not considered therapeutic goods.
Consumers should be alert to any misleading claims made online about MMS for the treatment, cure, prevention or alleviation of disease in humans, including COVID-19. Using MMS at higher concentrations or for purposes other than water purification can pose a serious risk to health. Using MMS in this way can cause nausea, vomiting, diarrhoea and severe dehydration. Consumers are strongly encouraged to talk to a health professional before using any unapproved product that makes therapeutic claims.
Health professionals should consider advising patients of the risks of using MMS at higher concentrations or for purposes other than water purification, as well as those associated with buying medicines over the internet and using any unapproved products that make therapeutic claims.
Please refer to the following website in TGA for details:
http://www.tga.gov.au/alert/miracle-mineral-solution-mms-0
In Hong Kong, the above product is not a registered pharmaceutical product. Related news was previously issued by various overseas drug regulatory authorities, and was posted on the Drug Office website since 2 Aug 2010, with the latest update posted on 18 Apr 2020.
Ends/Friday, May 8, 2020
Issued at HKT 15:00
|
| |
|
